Shape Memory Medical Inc. Company Profile
Background
Overview
Shape Memory Medical Inc. is a California-based medical device company specializing in innovative therapeutic solutions utilizing shape memory polymer (SMP) technology. Established in 2009, the company is recognized as the first to introduce an FDA-cleared medical device employing SMP technology in the vascular market.
Mission and Vision
The company's mission is to reshape clinical success through the science of smart polymers, aiming to drive a cross-specialty portfolio that meets the demands of current and future medical procedures. Their vision is to address challenging medical conditions by leveraging the unique properties of SMPs, thereby enhancing patient outcomes and advancing medical treatments.
Industry Significance
Shape Memory Medical stands out in the medical device industry for pioneering the application of SMP technology in vascular embolization. Their products offer unique properties such as vascular space-filling, radiolucency, low radial force, and stimulation of the immune response and healing system, setting new standards in embolization therapies.
Key Strategic Focus
Core Objectives
The company's primary objectives include advancing the clinical and market development of SMP technology for aortic and peripheral vascular markets, expanding their product pipeline, and increasing the adoption of their commercially available embolization devices.
Areas of Specialization
Shape Memory Medical specializes in endovascular embolization devices, focusing on peripheral vascular, cardiovascular, and neurovascular applications. Their expertise lies in developing catheter-deliverable, self-expanding embolic devices based on SMPs.
Key Technologies Utilized
The company utilizes proprietary SMP technology, which involves low-density, porous embolic materials that expand upon contact with blood, facilitating rapid conversion to organized thrombus. This technology offers unique properties, including vascular space-filling, radiolucency, low radial force, and stimulation of the immune response and healing system.
Primary Markets Targeted
Shape Memory Medical targets the aortic and peripheral vascular markets, focusing on conditions such as abdominal aortic aneurysms (AAA) and other vascular occlusions. Their products are designed to address the needs of these markets by providing innovative embolization solutions.
Financials and Funding
Funding History
As of March 2024, Shape Memory Medical has completed a Series C financing round, raising $38 million. This round was led by Earlybird Venture Capital, with participation from HBM Healthcare Investments, WexMed II LLC, HBM-Medfocus LLC, and Emergent Medical Partners II, L.P.
Total Funds Raised
The company has raised a total of $54 million across multiple funding rounds, including the Series C round in 2024.
Notable Investors
Key investors include Earlybird Venture Capital, HBM Healthcare Investments, WexMed II LLC, HBM-Medfocus LLC, and Emergent Medical Partners II, L.P.
Utilization of Capital
The funds from the Series C financing are intended to support the execution of the AAA-SHAPE Pivotal Trial, a randomized controlled study comparing endovascular aneurysm repair (EVAR) plus sac management with IMPEDE-FX RapidFill to stand-alone EVAR. Additionally, the capital will aid in the research and development of the company's product pipeline and the expansion of sales and marketing strategies to meet the increasing demand for their commercially available IMPEDE Embolization Plug family of devices.
Pipeline Development
Key Pipeline Candidates
The company's pipeline includes the IMPEDE-FX RapidFill® Device, an investigational device designed to improve abdominal aortic aneurysm (AAA) sac behavior when used with elective EVAR. The device is currently undergoing a prospective, multicenter, randomized, open-label trial to determine its safety and effectiveness.
Stages of Clinical Trials
The IMPEDE-FX RapidFill® Device is in the clinical trial phase, with the pivotal trial underway to assess its performance in improving AAA sac behavior.
Target Conditions
The primary target condition for this pipeline candidate is abdominal aortic aneurysms (AAA), aiming to enhance the outcomes of EVAR procedures.
Anticipated Milestones
The company anticipates completing the pivotal trial and obtaining regulatory approvals to bring the IMPEDE-FX RapidFill® Device to market, thereby expanding their product offerings in the vascular embolization space.
Technological Platform and Innovation
Proprietary Technologies
Shape Memory Medical's proprietary technology involves SMPs that are catheter-deliverable, crimpable, and self-expanding upon contact with blood. These materials are designed to produce rapid clot formation and progressive tissue healing as the material biodegrades.
Significant Scientific Methods
The company employs advanced polymer chemistry and formulation techniques to develop SMPs with specific properties tailored for medical applications. Their approach includes preclinical characterization, multicenter clinical studies, and regulatory approvals in multiple jurisdictions.
Leadership Team
Edward “Ted” Ruppel
- Position: President & CEO
- Professional Background: Over 25 years of experience in entrepreneurial and medical device company management, including roles at Micrus Endovascular Corp., Vascular Dynamics, and CBYON Inc.
- Contributions: Led the company since founding, focusing on the commercial advancement of SMP-based medical devices and driving clinical and regulatory strategies.
Other Leadership Members
Details regarding other members of the leadership team were not provided; however, the company emphasizes experienced management with backgrounds in medical technology development, commercialization, and regulatory affairs.
